Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13658256 | 0.80 | POLB (0.58) | POLBALDH1A1TDP1L3MBTL1IMPDH2 | |
| SCHEMBL13619987 | 0.76 | KRAS (0.47) | POLBALDH1A1TDP1L3MBTL1NPC1 | |
| SCHEMBL28597875 | 0.73 | XDH (0.43) | POLBALDH1A1TDP1L3MBTL1NPC1 | |
| SCHEMBL28323544 | 0.71 | ALDH1A1 (0.50) | TYRALDH1A1IMPDH2LMNAPTPN1 | |
| SCHEMBL26675294 | 0.70 | KMT2A (0.41) | POLBALDH1A1TDP1L3MBTL1IMPDH2 | |
| SCHEMBL24143350 | 0.69 | CYP2A6 (0.41) | POLBALDH1A1TDP1IMPDH2LMNA | |
| SCHEMBL18250323 | 0.69 | POLB (0.42) | POLBTDP1NPC1MAPTRAB9A | |
| SCHEMBL28596332 | 0.67 | XDH (0.45) | POLBALDH1A1TDP1L3MBTL1KDM4E | |
| SCHEMBL10193355 | 0.66 | ALDH1A1 (0.46) | POLBALDH1A1TDP1IMPDH2MAPT | |
| SCHEMBL24143364 | 0.65 | NR1D1 (0.56) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | TYR 3012/4885POLB 540/4885ALDH1A1 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.